1. Home
  2. GRI vs SOBR Comparison

GRI vs SOBR Comparison

Compare GRI & SOBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRI
  • SOBR
  • Stock Information
  • Founded
  • GRI 2018
  • SOBR 2004
  • Country
  • GRI United States
  • SOBR United States
  • Employees
  • GRI N/A
  • SOBR N/A
  • Industry
  • GRI Biotechnology: Pharmaceutical Preparations
  • SOBR Newspapers/Magazines
  • Sector
  • GRI Health Care
  • SOBR Consumer Discretionary
  • Exchange
  • GRI Nasdaq
  • SOBR Nasdaq
  • Market Cap
  • GRI 4.9M
  • SOBR 5.2M
  • IPO Year
  • GRI N/A
  • SOBR N/A
  • Fundamental
  • Price
  • GRI $1.77
  • SOBR $3.42
  • Analyst Decision
  • GRI Strong Buy
  • SOBR
  • Analyst Count
  • GRI 2
  • SOBR 0
  • Target Price
  • GRI $22.50
  • SOBR N/A
  • AVG Volume (30 Days)
  • GRI 207.8K
  • SOBR 86.8K
  • Earning Date
  • GRI 11-13-2025
  • SOBR 11-13-2025
  • Dividend Yield
  • GRI N/A
  • SOBR N/A
  • EPS Growth
  • GRI N/A
  • SOBR N/A
  • EPS
  • GRI N/A
  • SOBR N/A
  • Revenue
  • GRI N/A
  • SOBR $301,400.00
  • Revenue This Year
  • GRI N/A
  • SOBR N/A
  • Revenue Next Year
  • GRI N/A
  • SOBR N/A
  • P/E Ratio
  • GRI N/A
  • SOBR N/A
  • Revenue Growth
  • GRI N/A
  • SOBR 73.21
  • 52 Week Low
  • GRI $1.10
  • SOBR $2.41
  • 52 Week High
  • GRI $22.95
  • SOBR $69.39
  • Technical
  • Relative Strength Index (RSI)
  • GRI 42.57
  • SOBR 49.57
  • Support Level
  • GRI $1.89
  • SOBR $3.10
  • Resistance Level
  • GRI $2.27
  • SOBR $3.47
  • Average True Range (ATR)
  • GRI 0.17
  • SOBR 0.30
  • MACD
  • GRI -0.03
  • SOBR 0.00
  • Stochastic Oscillator
  • GRI 1.96
  • SOBR 45.71

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About SOBR SOBR Safe Inc.

Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.

Share on Social Networks: